Cardiotoxicity is a condition when there is damage to the heart muscle. It may be caused by chemotherapy drugs or medications concerning other diseases. As a result of cardiotoxicity, the heart becomes weaker and is unable to pump blood throughout the body.
DelveInsight’s “Cardiotoxicity Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Cardiotoxicity, historical and forecasted epidemiology as well as the Cardiotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some Key Highlights from the Cardiotoxicity Market Report:
- Cardiotoxicity was found in 39.6% of anthracycline-treated patients in a recent study (Sendon et al., 2020).
- Cardiotoxicity also seen in patients who were taking anti-HER2 (43.5%), anthracycline and anti-HER2 (45.7%), TKI (50%), left breast radiotherapy (44.8%), and mediastinal radiotherapy (29.1%). (Sendon et al., 2020).
- Around one-third of cancer patients who receive chemotherapy drugs including trastuzumab (Herceptin) and anthracyclines have heart cell damage (University of Michigan, n.d.).
- Cardiotoxicity pipeline therapies include Annamycin (Moleculin Biotech), Camsirubicin (Monopar Therapeutics), and others.
- Moleculin Biotech, Monopar Therapeutics, among others are the major pharmaceutical companies in the Cardiotoxicity market.
View Report: https://www.delveinsight.com/report-store/cardiotoxicity-market
To gain more insights request sample @ https://www.delveinsight.com/sample-request/cardiotoxicity-market
Cardiotoxicity Epidemiology Segmentation
- Various Cancer Total Incident Cases
- Various Cancer Total Number of Patients taking Chemotherapy
- Cardiotoxicity Total Number of Patients taking Specific Chemotherapy Agents
- Cardiotoxicity Total Number of Patients
Cardiotoxicity Treatment Landscape
- Dexrazoxan
- ACE inhibitors
- Beta-blockers
- Diuretics
- Digoxin
- Vasodilators
View Report: https://www.delveinsight.com/report-store/cardiotoxicity-market
To gain more insights request sample @ https://www.delveinsight.com/sample-request/cardiotoxicity-market
Some of the Cardiotoxicity Companies:
- Moleculin Biotech
- Monopar Therapeutics
- And Many Others
Cardiotoxicity Pipeline Therapies:
- Annamycin
- Camsirubicin
- And Many Others
View Report: https://www.delveinsight.com/report-store/cardiotoxicity-market
To gain more insights request sample @ https://www.delveinsight.com/sample-request/cardiotoxicity-market
Table of Contents
| 1. | Report Introduction |
| 2. | Executive Summary of Cardiotoxicity |
| 3. | Cardiotoxicity Market Overview at a Glance |
| 4. | Disease Background and Overview: Cardiotoxicity |
| 5. | Case Reports of Cardiotoxicity |
| 6. | Cardiotoxicity Patient Journey |
| 7. | Cardiotoxicity Epidemiology and Patient Population |
| 8. | Epidemiology of Cardiotoxicity by Countries (2018–2030) |
| 9. | Cardiotoxicity Treatments and Medical Practices |
| 10. | Cardiotoxicity Marketed Therapies |
| 11. | Cardiotoxicity Emerging Therapies |
| 12. | Cardiotoxicity Market Size |
| 13. | 7MM: Country-wise Market Analysis |
| 14. | Cardiotoxicity Market Drivers |
| 15. | Cardiotoxicity Market Barriers |
| 16. | SWOT Analysis |
| 17. | KOL Views |
| 18. | Reimbursement and market access |
| 19. | Report Methodology |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Site Title 